Elevated levels of C-reactive protein (OR 1.151, P=.007) and fibrinogen (OR 1.119, P=.005) were significantly associated with the presence of cardiac valve calcification in hemodialysis patients.
Observational (n=79)
Elevated inflammatory markers (CRP and fibrinogen) are associated with an increased risk of cardiac valve calcification in patients undergoing hemodialysis.
Effect estimate: OR 1.151 for CRP, OR 1.119 for fibrinogen
p-value: P=.007 for CRP, P=.005 for fibrinogen
BACKGROUND/AIMS: This study investigates the possible relationship between inflammation and cardiac valve calcification (VC) in patients on hemodialysis (HD), and identifies risk factors for VC in this patient group. METHODS: Seventy-nine patients on HD (mean age, 52.2 +/- 13.6 years; mean HD duration, 46.8 +/- 34.3 months) were assessed echocardiographically for the presence of VC. Systolic and diastolic blood pressure (BP) values were determined. The blood parameters studied in each case were hemoglobin, blood urea nitrogen, creatinine, calcium, phosphate, calcium-phosphorous (Ca x P) product, albumin, alkaline phosphatase, intact parathyroid hormone, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, lipoprotein(a), fibrinogen, and C-reactive protein (CRP). The number of patients receiving vitamin D and calcium-containing phosphate binder was determined from records, and presence of diabetes mellitus was noted. RESULTS: Cardiac VC was detected in 36 patients (46%). Five of these patients (6%) had mitral VC, 11 (14%) had aortic VC, and 20 (25%) had calcification of both valves. The patients with VC were significantly older than those without VC (60 +/- 11 vs. 43 +/- 15 years, respectively; P=.001). Compared with the group without VC, the group with calcification had significantly higher systolic (145.1 +/- 14.7 vs. 124.3 +/- 20.7 mmHg, P=.001) and diastolic BP (91.3 +/- 10.3 vs. 75.09 +/- 14.9 mmHg, P=.001); significantly higher phosphate (5.1 +/- 1.4 vs. 4.5 +/- 1.4 mg/dL, P=0.04), CaxP product (48.6 +/- 16.2 vs. 39.8 +/- 11.8, P=.01), lipoprotein(a) 28 (15, 45) vs. 16 (5,42) mg/dL, P=.04, fibrinogen (4.2 +/- 1.2 vs. 3.5-0.9, P=.005), and CRP levels 9 (4, 19) vs. 5 (3, 11) mg/L, P=.05; and significantly longer HD duration [49 (27, 99) vs. 26 (17, 52) month, P=.01). Apart from age, duration of HD, systolic and diastolic BP, and Ca x P product, VC was associated with CRP (odds ratio, 1.151; P=.007) and fibrinogen (odds ratio, 1.119; P=.005). CONCLUSIONS: The results confirm well-known risk factors for cardiac VC in HD patients, such as older age, longer HD duration, elevated BP, and high Ca x P product. In addition, they suggest that elevated levels of CRP and fibrinogen were associated with VC in the HD population.
Torun et al. (Sat,) conducted a observational in Hemodialysis (n=79). Elevated levels of C-reactive protein (OR 1.151, P=.007) and fibrinogen (OR 1.119, P=.005) were significantly associated with the presence of cardiac valve calcification in hemodialysis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: